Re: Farmas USA
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
25 September 2015
ORDER GRANTING CONF
IDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Novavax, Inc.
File No. 0-26770 -- CF# 32857
_____________________
Novavax, Inc. submitted an application
under Rule 24b-2 requesting confidential
treatment for information it excluded from th
e Exhibits to a Form 10-Q filed on August
10, 2015.
Based on representations by Novavax, Inc.
that this information qualifies as
confidential commercial or financial informa
tion under the Freedom of Information Act,
5 U.S.C. 552(b)(4), the Division of Corporat
ion Finance has determined not to publicly
disclose it. Accordingly, ex
cluded information from the follo
wing exhibit(s) will not be
released to the public for the time period(s) specified:
Exhibit 10.1 through December 31, 2016